Connect with us

Health Information Services

SAGILITY LIMITED (NSE: SAGILITY) clears resistance at ₹39, gains 6% intraday

SAGILITY LIMITED (NSE: SAGILITY) stock moves up 6% intraday, breaking above resistance at ₹39 with a fresh breakout..

Reena Bhati - Tradealone

Published

on

SAGILITY LIMITED NSE: SAGILITY clears resistance

SAGILITY LIMITED (SAGILITY) gained +6% to ₹42.04 on the NSE on 02 Jul 2026. The stock moved on a technical breakout, clearing the key resistance level at ₹39. Sagility operates in the healthcare information services sector, and today’s move appears to be company-specific rather than a sector-wide trend.

Technical setup — trendlines & DMA

From a technical perspective, Sagility’s stock is currently trading above both the 6-month support trendline at ₹38.3 and the resistance trendline at ₹39.48. The stock is now 8.90% above the support and has broken the resistance by 6.09%. The 50-day moving average (DMA) is below the 200-DMA, indicating a bearish trend, but the stock’s recent breakout suggests a potential shift in momentum. Currently, the stock is in the lower third of its 52-week range, indicating that there may be room for further upside if the breakout holds.

6M Trendline — Intraday Snapshot
BREAKOUT₹39.0₹40.0₹41.0₹42.018 May2 Jun17 Jun2 Jul

Snapshot: ₹42.04 on 2026-07-02 (chart frozen at publication)

Fundamentals & business context

Fundamentally, Sagility presents an interesting case. With a PE of 20.0, profit margins of 12.9%, and a revenue CAGR of 19.5%, the stock appears to be reasonably valued given its growth trajectory. The profit CAGR of 86.1% over the past five years underscores the company’s strong earnings growth. Institutional ownership stands at 20.6%, suggesting that smart money has a positive view on the company. There was no NSE catalyst today, indicating that the move was driven by technical factors rather than new fundamental information.

SAGILITY
Holdings Analysis
Key strengths & risk signals
73
Overall
86
Fundamental
61
Technical
Risks (3)
NEGLIGIBLE DIVIDEND! 0.69% yield - little to no income.
RECOVERY MODE! Current price (43.9) above 200-day but below 50-day.
WEAK YEAR! Stock declined 12.9% in the last year.
Strengths (4)
UNDERVALUED! PEG of 0.23 indicates stock is cheap relative to growth.
BULLISH TREND! 50-day average (44.4) is above 200-day average (42.6) - positive signal.
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 17,766,291 vs down days: 12,900,445. Ratio: 1.38x
NEUTRAL! RSI at 48.0 - balanced momentum.

Algorithmic scorecard

The overall algorithmic scorecard for Sagility reflects a balanced view, with strong fundamental signals offset by weaker technical indicators. Two of the strongest fundamental signals are the revenue CAGR of 19.5% and the profit CAGR of 86.1%, which highlight the company’s robust growth trajectory. Additionally, the PEG ratio of 0.23 indicates that the stock is undervalued relative to its growth, suggesting potential for future upside. On the weaker side, the technical indicators show a bearish trend with the 50-DMA below the 200-DMA and the stock trading below both moving averages. The stock’s position near the lower end of its 52-week range also suggests that it may be vulnerable to further downside if the breakout fails to hold.

Fundamental & Technical AnalysisNSE: SAGILITY
73Overall
86Fundamental
61Technical
Growth Quality28 / 30
Revenue CAGR: 19.5% (VERY GOOD, 13/15). Profit CAGR: 86.1% (EXCELLENT, 15/15).
Profit Margin5 / 10
DECENT EFFICIENCY! 12.8% profit margin - acceptable profitability.
PEG Valuation10 / 10
UNDERVALUED! PEG of 0.23 indicates stock is cheap relative to growth.
Dividend Yield3 / 10
NEGLIGIBLE DIVIDEND! 0.69% yield - little to no income.
Debt / Equity10 / 10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding20 / 20
VERY LESS PUBLIC HOLDING! 6.59% public ownership - strong promoter/institutional control.
Stability10 / 10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Moving Averages10 / 10
BULLISH TREND! 50-day average (44.4) is above 200-day average (42.6) - positive signal.
Price Position2 / 10
RECOVERY MODE! Current price (43.9) above 200-day but below 50-day.
Trend Pattern10 / 20
AT RESISTANCE! Stock is at key resistance level.
52W Performance2 / 10
WEAK YEAR! Stock declined 12.9% in the last year.
Volume Sentiment25 / 30
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 17,766,291 vs down days: 12,900,445. Ratio: 1.38x
RSI3 / 5
NEUTRAL! RSI at 48.0 - balanced momentum.
52W Range3 / 5
MID RANGE! Trading at 43.8% of 52W range - neutral zone.
Momentum3 / 5
MIXED MOMENTUM! Price growth is inconsistent - 0.9% (1 week), -3.7% (1 month), 3.8% (3 months).
Beta / Volatility3 / 5
MARKET ALIGNED! Beta of 1.00 - moves with the market.

Company outlook

Management provided forward guidance for FY ’27, indicating low double-digit growth in constant currency and an adjusted EBITDA margin between 24% and 25%. They expect seasonal revenues to continue with a 54.5% to 45% split between H2 and H1. The pipeline of total contract value (TCV) is expected to be between ₹570 million and ₹575 million. Management remains qualitatively bullish on client conversations despite longer deal timings. They plan to repay the remaining debt by the end of FY ’27 and will focus on managed service deals and transformational conversations with clients.

Get all details on SAGILITY — P&L, peers, shareholding and more on TradeAlone.

Health Information Services

Indegene Limited (indgn) Q2 FY27: Revenue Up 39.5% Yoy, H1 USD Revenue Growth at Four-year High

Indegene Limited (INDGN) reports strong Q2 FY27 performance with 39.5% YoY revenue growth and H1 USD revenue hitting a four-year high.

jyoti sharma

Published

on

Indegene Limited INDGN Q2 FY27 Results

Indegene Limited (INDGN), the strategic operating partner to the global life sciences industry, announced its financial results for the quarter ended September 30, 2026. Indegene’s Q2 FY27 performance showcased a robust revenue growth of 39.5% year-on-year (YoY) in INR, translating to a 27.5% YoY increase in USD. This marks the fifth successive quarter of above 5% sequential growth. The company’s revenue for the quarter stood at ₹11,223 million ($117.5 million), with an EBITDA of ₹1,873 million, marking a 32.0% YoY increase. Moreover, H1 USD revenue growth reached a four-year high, reflecting the company’s sustained deal momentum and favorable industry tailwinds.

Revenue and Profitability

Indegene’s revenue from operations increased significantly to ₹11,223 million, up from ₹8,042 million in the same quarter last year. The company’s EBITDA margin remained stable at 16.7%, despite wage hikes, while the profit after tax (PAT) grew by 10% YoY to ₹1,123 million. This strong performance is attributed to the expansion across top accounts and an increase in the number of $1 million+ clients to 59, including 13 in the $10M+ range.

Growth and Future Outlook

Manish Gupta, Chairman and CEO of Indegene, highlighted the company’s broad-based growth driven by expansion across top accounts and significant deal wins in GenAI-enabled transformation and upstream engagements. Suhas Prabhu, CFO, noted that with a healthy pipeline and sustained deal momentum, Indegene expects growth and margin expansion to come together in the second half. The company anticipates EBITDA to grow faster than revenue in the coming quarters, supported by higher yields on investments and lower amortization.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Indegene Limited

Indegene Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

INDGN
Healthcare › Health Information Services
BREAKOUT
62
Fundamental
80
Technical
71
Overall

1W +9.26%
1M +11.61%
3M +19.86%
P/E: 39.2 Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Indegene gains 17.1% over three months and trades near its 52-week highs. The PEG of 2.45 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock trades at 86% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 17.1% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.

Continue Reading

Health Information Services

Sagility Limited (NSE: Sagility) Q2 FY27: 11.9% Y-o-y Constant Currency Organic Growth

Sagility Limited (NSE: SAGILITY) reports Q2 FY27 results with 11.9% Y-o-Y constant currency organic growth and $40.2M ACV.

Pranab Tyagi at TradeAlone

Published

on

Sagility Limited NSE Sagility Q2 FY27 Results

Sagility Limited (NSE: SAGILITY) has announced its Q2 FY27 results, showcasing robust performance with 11.9% year-over-year constant currency organic growth. The company won $40.2M in ACV from 31 existing clients and 1 new logo, indicating increasing traction in larger deals.

Financial Highlights

The financial performance highlights include a revenue of ₹ 20,321 Million, an Adjusted EBITDA of ₹ 5,353 Million, and an Adjusted PAT of ₹ 3,254 Million. The company’s margin stood at 26.3% for Adjusted EBITDA and 16.0% for Adjusted PAT.

Growth and Expansion

Sagility’s growth is further supported by its acquisition of Chirok Health LLC, which adds specialized CDI and coding capabilities, extending its end-to-end RCM offering and unlocking new growth opportunities. The acquisition is expected to broaden Sagility’s provider footprint and deliver greater client value.

As a result, Sagility continues to strengthen its market position and drive forward-looking growth prospects.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of SAGILITY LIMITED

SAGILITY LIMITED belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

SAGILITY
Healthcare › Health Information Services
APPROACHING RESISTANCE
86
Fundamental
60
Technical
73
Overall

1W +0.94%
1M -3.69%
3M +3.76%
P/E: 19.9 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

SAGILITY rises 8.5% over three months, with buying pressure holding steady. The PEG of 0.25 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 19.5% and profits at 86.1% CAGR. That is strong double-digit growth on both counts. The stock holds at 43% of its 52-week range with RSI at 56. In other words, neither side has a clear edge right now. Revenue grows at 19.5% and profits at 86.1%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of SAGILITY LIMITED.

Continue Reading

Health Information Services

Indegene Limited (indgn) Wins Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition

Indegene Limited (INDGN) wins Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition for AI-powered pharma commercialization.

Deputy Editor, Equities for tradealone

Published

on

Indegene Limited INDGN 2026 Recognition

Indegene Limited (INDGN) has been honored with Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition for its outstanding achievements in AI-powered pharma commercialization. This recognition underscores Indegene’s leadership in transforming pharmaceutical commercialization workflows through domain-led AI, knowledge orchestration, and integrated execution.

Recognition Highlights

Frost & Sullivan commends Indegene for its ability to align its AI strategy with the evolving needs of the pharmaceutical industry while executing at scale across commercial, medical, regulatory, safety, analytics, content, and field engagement workflows. The recognition highlights Indegene’s leadership in modernizing complex commercialization processes through domain expertise, technology, data, and execution support.

Innovative Approach

Indegene’s Pharma Operating System (OS) connects business decisions, workflow execution, and intelligence across the enterprise, helping pharmaceutical organizations replace fragmented processes with integrated and adaptive operating models. Its Cortex life sciences-native reasoning engine enables subject matter experts to codify specialized knowledge, creating validated knowledge graphs and guiding AI-enabled workflows.

Forward-Looking Strategy

The company’s commitment to customer experience strengthens its market position by connecting strategy, data, content, execution, and measurable outcomes. Indegene’s platform-agnostic approach allows customers to work in existing technology environments, reducing adoption friction while protecting existing technology investments. This recognition reinforces Indegene’s belief in the next wave of value creation through connecting intelligence, decisions, and execution across the enterprise.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Indegene Limited

Indegene Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

INDGN
Healthcare › Health Information Services
BREAKOUT
62
Fundamental
80
Technical
71
Overall

1W +9.26%
1M +11.61%
3M +19.86%
P/E: 39.2 Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Indegene gains 17.1% over three months and trades near its 52-week highs. The PEG of 2.45 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock trades at 86% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 17.1% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.

Continue Reading

Trending